OmniAb Inc. announced the signing of a technology license and services agreement with Mabtrx Biosciences, a subsidiary of AMVKG LS, which is a joint venture between ArrowMark Partners and Viking Global Investors. The agreement focuses on the use of OmniAb's OmnidAb™ single domain technology for antibody discovery programs. Under the terms of the agreement, OmniAb will receive revenue for discovery services performed, as well as potential equity and royalties related to the discovery of novel antibodies for targets defined by Mabtrx.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117801230) on November 17, 2025, and is solely responsible for the information contained therein.